AVITA Medical (ASX:AVH) Marketable Securities: A$8.5 Mil (As of Mar. 2026)


ASX:AVH AVITA Medical Inc ASX:AVH
60 GF Score
Price A$1.24
GF Value A$3.28
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is AVITA Medical Marketable Securities?

AVITA Medical ASX:AVH -7.49% 60 Marketable Securities is A$8.5 Mil as of Mar. 2026. GuruFocus rates ASX:AVH with a GF Score™ of 60/100 and a GF Value™ of A$3.28 (Possible Value Trap). The stock has 6 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. AVITA Medical's Marketable Securities for the quarter that ended in Mar. 2026 was A$8.5 Mil.

AVITA Medical's annual Marketable Securities declined from Dec. 2023 (A$100.0 Mil) to Dec. 2024 (A$34.5 Mil) and declined from Dec. 2024 (A$34.5 Mil) to Dec. 2025 (A$12.0 Mil).

AVITA Medical  (ASX:AVH) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

AVITA Medical Marketable Securities Related Terms

AVITA Medical Marketable Securities Historical Data

* Premium members only.

The historical data trend for AVITA Medical's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AVITA Medical Marketable Securities Chart

AVITA Medical Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 90.67 100.01 34.48 11.95

AVITA Medical Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.37 5.34 11.96 11.95 8.48
ASX:AVH
60GF Score
AVITA Medical Inc ASX:AVH
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AVITA Medical Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of A$8.5 Mil mean?
AVITA Medical (ASX:AVH) has a Marketable Securities of A$8.5 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on AVITA Medical and its competitors.
Is AVITA Medical's Marketable Securities too high?
AVITA Medical's current Marketable Securities is A$8.5 Mil. Overall, AVITA Medical has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does AVITA Medical's Marketable Securities compare to MXCT and HYPR?
AVITA Medical's Marketable Securities of A$8.5 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Medical Devices & Instruments company?
A good Marketable Securities depends on the Medical Devices & Instruments industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on AVITA Medical and its competitors. AVITA Medical's current Marketable Securities is A$8.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AVITA Medical stock overvalued right now?
Based on GuruFocus' analysis, AVITA Medical (ASX:AVH) is currently considered Possible Value Trap. The stock's GF Value™ is A$3.28, compared to a current price of A$1.24 — trading 62.3% below its estimated fair value. The current Marketable Securities is A$8.5 Mil. AVITA Medical's overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For AVITA Medical (ASX:AVH), the current Marketable Securities is A$8.5 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AVITA Medical (ASX:AVH) Overvalued in 2026?

Based on GuruFocus' analysis, AVITA Medical stock appears to be undervalued. The current stock price of A$1.24 is trading 62.3% below its estimated GF Value™ of A$3.28. GuruFocus considers AVITA Medical to be Possible Value Trap.

Key valuation signals for ASX:AVH:

  • Marketable Securities: A$8.5 Mil
  • GF Value™: A$3.28 vs. price of A$1.24 (62.3% below fair value)
  • GF Score™: 60/100 with 6 warning signs

No single metric tells the full story. See the ASX:AVH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AVITA Medical Business Description

Address 28159 Avenue Stanford, Suite 220, Valencia, Santa Clarita, CA, USA, 91355
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.
60GF Score

Get the complete analysis for ASX:AVH

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$1.24
Price
A$3.28
GF Value